Locations:
Search IconSearch
June 17, 2024/Neurosciences/Podcast

Migraine Relief: Providing Preventive and Abortive Therapies (Podcast)

A close look at the growing array of options for episodic and chronic migraine

Approximately 16% to 20% of women and 6% to 10% of men suffer from migraine. In 2018, a revolutionary class of preventive monoclonal antibodies — the calcitonin gene-related peptide (CGRP) receptor antagonists — was introduced to treat migraine.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The number of new therapies and medications that have recently emerged for the treatment of migraine is unmatched in all other branches of neurology,” says headache specialist Emad Estemalik, MD, MBA, Section Head of Headache and Facial Pain in Cleveland Clinic’s Neurological Institute. “We have been fortunate to welcome a disproportionate share of new interventions.”

In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Estemalik explores the current landscape of preventive and abortive therapies for the management of migraine. He discusses the following:

  • What constitutes chronic and episodic migraine
  • How preventive monoclonal antibodies act in the calcitonin gene-related peptide receptor
  • Delivery methods and potential side effects of CGRP receptor antagonists
  • The importance of lifestyle modifications in migraine prevention
  • Advancements on the horizon, including research on the pituitary adenylate cyclase-activating peptide (PACAP)

Advertisement

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

This activity has been approved for AMA PRA Category 1 Credit™ and ANCC contact hours. After listening to the podcast, you can claim your credit here.

Excerpt from the podcast

Podcast host Glen Stevens, DO, PhD: If I am a migraine patient and I take abortive medications, how much is too much? When should I be put on one of these newer drugs for migraine prevention?

Dr. Estemalik: There are two components to the answer. The frequency of abortive medication use definitely plays a role. If patients are requiring more than two days a week of some abortive, I think it's time to consider a preventive to reduce the use of abortive medication.

Second, it’s often important to also pinpoint exactly the number of headache days a patient is having. A patient can tell you, “I only have four migraines a month.” If those migraines are not adequately treated and you ask how long the migraines last, the patient may say they last three to four days. At that point the patient is already at 12 to 16 headache days a month.

So while the frequency of abortive medications is critical, so is the number of headache days and the degree of debilitation. We really need to understand how patients’ quality of life is affected. Are they missing out on work, social activities, family activities? It’s a matter of putting all of that in context. And that is where we do a phenomenal job at a place like Cleveland Clinic, where our use of patient-reported outcome measures and questionnaires gives us a much deeper understanding beyond just quantitative assessments.

Related Articles

Dr. Amy Kunchok against decorative background
July 16, 2024/Neurosciences/Podcast
What to Know About Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) (Podcast)

It’s time to get familiar with this emerging demyelinating disorder

receptor activity for myasthenia gravis medications
July 3, 2024/Neurosciences/Podcast
Myasthenia Gravis: Unmet Needs and Efforts to Address Them (Podcast)

An overview of associated antibodies, therapies for antibody-positive disease and the outlook for atypical forms of MG

woman grabbing her back in pain
June 3, 2024/Neurosciences/Podcast
Shedding Light on Stiff Person Syndrome (Podcast)

Heightened awareness of this rare disorder may lead to better diagnosis and treatment progress

pills, syringes and vials on a tabletop
May 15, 2024/Neurosciences/Podcast
Multiple Sclerosis Medications: Making the Most of a Multitude of Options (Podcast)

Insights on the decision process for selecting a treatment approach

doctor applying force to patient's forearm to test strength
Offering Rehabilitation Care to Oncology Patients (Podcast)

New oncologic rehab program is tailored to managing the effects of cancer and its treatments

syringe being prepared for injection
April 15, 2024/Neurosciences/Podcast
Balancing Benefits and Pitfalls of Neurotoxin Injections (Podcast)

Determining the right dose and injecting in the right muscle can be challenging

inflammation on a brain scan with a podcast button overlay
April 2, 2024/Neurosciences/Podcast
Diagnosis and Management of Cerebral Amyloid Angiopathy-Related Inflammation (Podcast)

New research sheds light on a potentially devastating condition that is reversible when properly managed

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

Ad